In this special edition of Patient Power, Andrew Schorr takes follow-up questions from listeners about the latest news and treatment options for patients with multiple myeloma. In the last program, The Latest Myeloma News from the American Society of Hematology meeting , Andrew interviewed three renowned experts, Dr. Brian Durie, Dr. James Berenson and Dr. Sagar Lonial, about the latest and most exciting news from the ASH conference held in Atlanta. This is a follow-up to that program and features Dr. Thomas Heffner answering your most pressing questions.
Dr. Heffner, associate professor of Hematology/Oncology and Internal Medicine at Emory University in Atlanta and clinical director of the Myeloma Program at the Winship Cancer Center Institute, discusses what he’s excited about with the news from the American Society of Hematology meeting in Atlanta, including his thoughts on transplant and the use of Velcade for the treatment of recurrent myeloma. He fields a variety of additional questions from the Patient Power audience providing further information regarding clinical trials, drug combinations, stem cell transplants, treatment options for patients with kidney disease, side effects of the different therapies, remission, and quality of life.
Dr. Heffner speaks about the tremendous progress being made in myeloma research and how new developments are prolonging remission and survival and improving quality of life. If you have questions about multiple myeloma, you can find the answers in this very informative Patient Power program.
|
L. Thomas Heffner, Jr. M.D.
Associate Professor of Hematology and Oncology, Winship Cancer Institute, Emory Healthcare
Dr. Heffner is Associate Professor of Hematology and Oncology at The Emory Clinic in Atlanta. His clinical interests include treatment of Hodgkin’s disease, bone marrow treatment, leukemia, lymphomas and multiple myeloma. Dr. Heffner earned his medical degree from Bowman Gray School of Medicine in Winston-Salem, NC, and completed residency training at both Emory and at Baylor University School of Medicine...
more >
|
|
|

